Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01XQQ
|
|||
| Former ID |
DIB009604
|
|||
| Drug Name |
TT-30
|
|||
| Synonyms |
CR2/factor H modulator (fusion protein, autoimmune/inflammatory disease), Alexion; CR2/factor H modulator (fusion protein, autoimmune/inflammatory disease), Taligen
Click to Show/Hide
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 1 | [1] | |
| Company |
Taligen Therapeutics Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement factor H (CFH) | Target Info | Modulator | [2] |
| Complement receptor type 2 (CD21) | Target Info | Modulator | [2] | |
| KEGG Pathway | Complement and coagulation cascades | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Epstein-Barr virus infection | ||||
| Staphylococcus aureus infection | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Notch Signaling Pathway | ||||
| TCR Signaling Pathway | ||||
| IL1 Signaling Pathway | ||||
| Reactome | Regulation of Complement cascade | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| B Cell Receptor Signaling Pathway | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01335165) Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH). U.S. National Institutes of Health. | |||
| REF 2 | The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28;119(26):6307-16. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.